Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data

Urology

Volumn 84, Issue 1, 2014, Pages 122-126

  Witjes, J Alfred ^a   Gomella, Leonard G ^b   Stenzl, Arnulf ^c   Chang, Sam S ^d   Zaak, Dirk ^e   Grossman, H Barton ^f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e Clinic Traunstein   (Germany)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

ADVERSE OUTCOME; AGED; ARTICLE; BLADDER CANCER; BLUE LIGHT; BLUE LIGHT CYSTOSCOPY; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; SINGLE DRUG DOSE; URINARY TRACT INFECTION; WHITE LIGHT; WHITE LIGHT CYSTOSCOPY;

AGED; AMINOLEVULINIC ACID; CONTROLLED CLINICAL TRIALS AS TOPIC; CYSTOSCOPY; DRUG APPROVAL; FEMALE; HUMANS; LIGHT; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; URINARY BLADDER NEOPLASMS;

EID: 84903713396     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.03.006     Document Type: Article

References (23)

1. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials Eur Urol 49 2006 466 477
2. I. Kausch, M. Sommerauer, and F. Montorsi et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies Eur Urol 57 2010 595 606
3. A. Stenzl, M. Burger, and Y. Fradet et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer J Urol 184 2010 1907 1913
4. G.G. Hermann, K. Mogensen, and S. Carlsson et al. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study BJU Int 108 8 Pt 2 2011 E297 E303
5. P. Jichlinski, L. Guillou, and S.J. Karlsen et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study J Urol 170 2003 226 229
6. J. Schmidbauer, F. Witjes, and N. Schmeller et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy J Urol 171 2004 135 138
7. H.B. Grossman, L. Gomella, and Y. Fradet et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer J Urol 178 2007 62 67
8. Y. Fradet, H.B. Grossman, L. Gomella PC B302/01 Study Group A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study J Urol 178 2007 68 73
9. D. Jocham, F. Witjes, and S. Wagner et al. Improved detection and treatment of bladder cancer using Hexvix® imaging: a prospective phase III multi-centre study J Urol 174 2005 862 866
10. H.B. Grossman, A. Stenzl, and Y. Fradet et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy J Urol 188 2012 58 62
11. M. Babjuk, W. Oosterlinck, and R. Sylvester et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
12. H.I. Scher, and R.J. Motzer Bladder and renal cell cancer D.L. Kasper, Harrison's Principles of Internal Medicine 16th ed. 2005 McGraw-Hill New York 539 943
13. Bock R. Cancer of the Bladder. Research Report. National Cancer Institute, Office of Cancer Communications; Bethesda, MD.
14. C.L. Pashos, M.F. Botteman, and B.L. Laskin et al. Bladder cancer: epidemiology, diagnosis, and management Cancer Pract 10 2002 311 322
15. G.L. Shaw, and C.J. Bunce Fluorescence cystoscopy - how to do it Photodiagnosis Photodyn Ther 5 2008 267 270
16. B.B. Kortmann, G.S. Sonke, and F.C. D'Ancona et al. The tolerability of urodynamic studies and flexible cysto-urethroscopy used in the assessment of men with lower urinary tract symptoms BJU Int 84 1999 449 453
17. D.M. Burke, D.C. Shackley, and P.H. O'Reilly The community-based morbidity of flexible cystoscopy BJU Int 89 2002 347 349
18. Y.Z. Almallah, C.D. Rennie, and J. Stone et al. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation Urology 56 2000 37 39
19. K.R. Clark, and M.J. Higgs Urinary infection following out-patient flexible cystoscopy Br J Urol 66 1990 503 505
20. S.W. Denholm, I.G. Conn, and J.E. Newsam et al. Morbidity following cystoscopy: comparison of flexible and rigid techniques Br J Urol 66 1990 152 154
21. Medline Plus, The U.S. National Library of Medicine and the National Institutes of Health. Bladder cancer. Available at: http://www.nlm.nih.gov/ medlineplus/ency/article/000486.htm. Accessed 20 April 2009.
22. R. Madeb, and E.M. Messing Gender, racial and age differences in bladder cancer incidence and mortality Urol Oncol 22 2004 86 92
23. L. Colapaoli, J. Thorsen, and A. Nopp et al. A case of anaphylactic shock possibly caused by intravesical Hexvix Acta Anaesthesiol Scand 50 2006 1165 1167